Prelude Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
PRLD$3.760.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2023 and 2022
BALANCE SHEETS
| December 31, | ||
|---|---|---|
| (in thousands, except share and per share data) | 2023 | 2022 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $25,291 | $30,605 |
| Marketable securities | 207,644 | 171,123 |
| Prepaid expenses and other current assets | 2,654 | 2,652 |
| Total current assets | 235,589 | 204,380 |
| Restricted cash | 4,044 | 4,044 |
| Property and equipment, net | 7,325 | 4,908 |
| Right-of-use asset | 30,412 | 1,792 |
| Prepaid expenses and other non-current assets | 295 | 5,376 |
| Total assets | $277,665 | $220,500 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $4,580 | $6,777 |
| Accrued expenses and other current liabilities | 15,768 | 13,093 |
| Operating lease liability | 1,481 | 1,832 |
| Total current liabilities | 21,829 | 21,702 |
| Other liabilities | 3,339 | 3,361 |
| Operating lease liability | 15,407 | — |
| Total liabilities | 40,575 | 25,063 |
| Commitments (note 8) | ||
| Stockholders’ equity: | ||
| Voting common stock, $0.0001 par value: 487,149,741 shares authorized; 42,063,995 and 36,496,994 shares issued and outstanding at December 31, 2023 and 2022, respectively | 4 | 4 |
| Non-voting common stock, $0.0001 par value: 12,850,259 shares authorized; 12,850,259 and 11,402,037 shares issued and outstanding at December 31, 2023 and 2022, respectively | 1 | 1 |
| Additional paid-in capital | 693,252 | 531,682 |
| Accumulated other comprehensive income (loss) | 223 | (1,692) |
| Accumulated deficit | (456,390) | (334,558) |
| Total stockholders’ equity | 237,090 | 195,437 |
| Total liabilities and stockholders’ equity | $277,665 | $220,500 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.